Evaluation of the immunity level achieved with the oral polio vaccine in schoolchildren aged 6 to 12 years of Catalonia (Spain);Evaluación del grado de protección inmunitaria conseguida con la vacuna oral antipoliomielítica en la población infantil de 6-12 años de Cataluña

Medicina Clinica

Volumn 127, Issue 16, 2006, Pages 612-614

  Rubió, Pedro Plans ^a,c   García, Núria Rabella ^b   Zabalo, Magdalena Otegui ^b   Vendrell, Jordi Espuñes ^a   García, Ángela Domínguez ^a   Taradach, Antoni Plasència ^a  

^a GENERALITAT DE CATALUNYA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

Author keywords

Evaluative studies; Oral polio vaccine (OPV); Poliomyelitis; Prevalence of antibodies

Indexed keywords

ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; SPAIN; VACCINATION; VIRUS IMMUNITY;

EID: 33845393936     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13094418     Document Type: Article

References (10)

1. Departament de Salut. Pla de Salut de Catalunya 2000-2005. Barcelona: Departament de Salut; 2003.
2. WHO. Progress toward global poliomyelitis eradication, 2000. Wkly Epidemiol Rec. 2001;76:126-32.
3. CDC. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50:222-4.
4. Navarro Alonso JA, De Arístegui Fernández J. Perspectives en la erradicación de las infecciones prevenibles por vacunación. Med Clin (Barc). 2002;119:574-8.
5. WHO. Manual for the virological investigation of polio. Global Programme for Vaccines and Immunization. Expanded Programme on Immunization. Geneva: WHO; 1997.
6. Salk J. Immunization against poliomyelitis: risk/benefit/cost in a changing context. Dev Biol Stand. 1979;43:151-7.
7. Mas Lago P, Ramon Bravo J, Andrus JK, Comellas MM, Galindo MA, De Cuadros CA, et al. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull World Health Organ. 1994;72:221-5.
8. Jee YM, Cheon DS, Kim KS, Lee SH, Yoon JD, Lee SW, et al. A seroprevanlence study of poliovirus antibody among primary schoolchildren in Korea. Epidemiol Infect. 2004;132:351-5.
9. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA. 1996;275:1639-15.
10. Anderson RM. The concept of heard immunity and the design of community-based immunization programmes. Vaccine. 1992;10:928-35.